Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat and host one-on-one meetings at the Piper Sandler
View HTML
Toggle Summary Veracyte Announces New General Manager Structure to Advance Global Expansion
John Hanna appointed GM , endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM , pulmonology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 17, 2020-- Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster
View HTML

Events

Date Event Details
Summary Toggle Dec 1 - Dec 3, 2020
Piper Sandler 32nd Annual Virtual Healthcare Conference

Presentations

Title Documents

Corporate Presentation November 2020